Text Size

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00556998
First received: November 9, 2007
Last updated: February 27, 2012
Last verified: February 2012
History of Changes
Results First Received: August 2, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Pharmacokinetics
Intervention: Drug: Voriconazole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Treatments Voriconazole intravenous (IV) loading dose (6 mg/kg) was administered in the morning and evening on Day 1, and the IV maintenance dose (4 mg/kg) was administered in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated). The oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Participant Flow for 2 periods

 Period 1:   Voriconazole Intravenous (IV)
    All Treatments  
STARTED     26  
Treated     26  
COMPLETED     21 [1]
NOT COMPLETED     5  
Adverse Event                 1  
unspecified                 4  
[1] One participant received 2 days of oral; then received IV again before discontinuing from study.

Period 2:   Voriconazole Oral
    All Treatments  
STARTED     22 [1]
COMPLETED     20  
NOT COMPLETED     2  
Adverse Event                 1  
Intolerant of oral treatment                 1  
[1] One participant received voriconazole 150 mg every 12 hours during oral phase.



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
All Treatments Voriconazole intravenous (IV) loading dose (6 mg/kg) was administered in the morning and evening on Day 1, and the IV maintenance dose (4 mg/kg) was administered in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated). The oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Baseline Measures
    All Treatments  
Number of Participants  
[units: participants]
 		  26  
Age, Customized  
[units: Years]
 		 
12     4  
13     10  
>13 to <17     12  
Gender, Customized  
[units: Participants]
 		 
Female     9  
Male     17  



  Outcome Measures
  Hide All Outcome Measures

1.  Primary:   Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Primary
Measure Title Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
Measure Description AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time Frame Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent to treat (ITT) population of participants who had completed pharmacokinetic (PK) blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  23  
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration  
[units: μg*h/mL]
Geometric Mean ± Standard Deviation 		  22.39  ± 21.47  

No statistical analysis provided for Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration



2.  Primary:   Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Primary
Measure Title Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  23  
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		  3.89  ± 2.59  

No statistical analysis provided for Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration



3.  Primary:   Time to Reach Cmax (Tmax) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Primary
Measure Title Time to Reach Cmax (Tmax) Following IV Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  23  
Time to Reach Cmax (Tmax) Following IV Administration  
[units: hours]
Median ( Full Range ) 		  1.30  
  ( 1.17 to 3.95 )  

No statistical analysis provided for Time to Reach Cmax (Tmax) Following IV Administration



4.  Primary:   AUC12,ss Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Primary
Measure Title AUC12,ss Following Oral Administration
Measure Description AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time Frame Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
AUC12,ss Following Oral Administration  
[units: μg*h/mL]
Geometric Mean ± Standard Deviation 		  16.74  ± 13.50  

No statistical analysis provided for AUC12,ss Following Oral Administration



5.  Primary:   Cmax,ss Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Primary
Measure Title Cmax,ss Following Oral Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
Cmax,ss Following Oral Administration  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		  2.35  ± 1.41  

No statistical analysis provided for Cmax,ss Following Oral Administration



6.  Primary:   Tmax Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Primary
Measure Title Tmax Following Oral Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
Tmax Following Oral Administration  
[units: hours]
Median ( Full Range ) 		  2.00  
  ( 0.67 to 8.10 )  

No statistical analysis provided for Tmax Following Oral Administration



7.  Secondary:   AUC12 Following IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title AUC12 Following IV Loading Dose
Measure Description AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1.

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  22  
AUC12 Following IV Loading Dose  
[units: μg*h/mL]
Geometric Mean ± Standard Deviation 		  9.14  ± 4.90  

No statistical analysis provided for AUC12 Following IV Loading Dose



8.  Secondary:   Tmax Following an IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title Tmax Following an IV Loading Dose
Measure Description No text entered.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1.

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  22  
Tmax Following an IV Loading Dose  
[units: hours]
Median ( Full Range ) 		  1.97  
  ( 1.90 to 2.08 )  

No statistical analysis provided for Tmax Following an IV Loading Dose



9.  Secondary:   Cmax Following an IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title Cmax Following an IV Loading Dose
Measure Description No text entered.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1.

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  22  
Cmax Following an IV Loading Dose  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		  2.25  ± 0.86  

No statistical analysis provided for Cmax Following an IV Loading Dose



10.  Secondary:   Minimum Observed Plasma Trough Concentration (Cmin)   [ Time Frame: Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose ]

Measure Type Secondary
Measure Title Minimum Observed Plasma Trough Concentration (Cmin)
Measure Description No text entered.
Time Frame Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data; n = number of participants who contributed to data.

Reporting Groups
  Description
All Treatments Voriconazole intravenous (IV) loading dose (6 mg/kg) was administered in the morning and evening on Day 1, and the IV maintenance dose (4 mg/kg) was administered in the morning and evening on Days 2-7 (up to Day 20 if clinically indicated). The oral maintenance dosing regimen was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    All Treatments  
Number of Participants Analyzed  
[units: participants]
 		  21  
Minimum Observed Plasma Trough Concentration (Cmin)  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		 
IV Day 7 (up to Day 20) (n=21)     1.05  ± 1.85  
Oral Day 7 (up to Day 30) (n=19)     0.72  ± 0.81  

No statistical analysis provided for Minimum Observed Plasma Trough Concentration (Cmin)



11.  Secondary:   AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Measure Description AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  25  
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration  
[units: μg*h/mL]
Geometric Mean ± Standard Deviation 		 
Day 1     21.18  ± 6.80  
Day 7 (up to Day 20)     36.21  ± 9.20  

No statistical analysis provided for AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration



12.  Secondary:   Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Measure Description No text entered.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  25  
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		 
Day 1     2.50  ± 0.84  
Day 7 (up to Day 20)     3.48  ± 0.73  

No statistical analysis provided for Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration



13.  Secondary:   Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]

Measure Type Secondary
Measure Title Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Measure Description No text entered.
Time Frame Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole IV Voriconazole IV loading dose (6 mg/kg) in the morning and evening on Day 1 and multiple IV doses (4 mg/kg) in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated).

Measured Values
    Voriconazole IV  
Number of Participants Analyzed  
[units: participants]
 		  25  
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration  
[units: μg*h/mL]
Median ( Full Range ) 		 
Day 1     4.00  
  ( 1.97 to 8.03 )  
Day 7 (up to Day 20)     4.03  
  ( 0.00 to 12.10 )  

No statistical analysis provided for Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration



14.  Secondary:   AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Secondary
Measure Title AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Measure Description AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time Frame On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration  
[units: μg*h/mL]
Geometric Mean ± Standard Deviation 		  44.07  ± 13.86  

No statistical analysis provided for AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration



15.  Secondary:   Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Secondary
Measure Title Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration  
[units: μg/mL]
Geometric Mean ± Standard Deviation 		  4.44  ± 1.43  

No statistical analysis provided for Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration



16.  Secondary:   Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]

Measure Type Secondary
Measure Title Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Measure Description No text entered.
Time Frame Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population of participants who had completed PK blood sampling for at least one day. N = number of participants with analyzable data.

Reporting Groups
  Description
Voriconazole Oral Oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Measured Values
    Voriconazole Oral  
Number of Participants Analyzed  
[units: participants]
 		  19  
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration  
[units: hours]
Median ( Full Range ) 		  5.97  
  ( 1.00 to 8.10 )  

No statistical analysis provided for Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration



17.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Loading Dose.   [ Time Frame: Day 1 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

18.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Steady State   [ Time Frame: Day 7 of IV dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

19.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral Dose All Subjects   [ Time Frame: Day 7 Oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

20.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral 300mg   [ Time Frame: Day 7 oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

21.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Loading Dose   [ Time Frame: Day 1 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

22.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Steady State   [ Time Frame: Day 7 of Intravenous dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

23.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax Day 7 Oral All Participants   [ Time Frame: Day 7 of oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

24.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax 300 mg Oral Dose   [ Time Frame: Day 7 of oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00556998     History of Changes
Other Study ID Numbers: A1501081
Study First Received: November 9, 2007
Results First Received: August 2, 2010
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration